$OMER News

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab

Omeros shares slide following European regulatory setback for Narsoplimab

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Cantor Fitzgerald Reiterates Overweight on Omeros, Maintains $22 Price Target

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

Cantor Fitzgerald Upgrades Omeros to Overweight, Announces $22 Price Target

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) Turns Profitable As Investors Ask If The Repricing Has Gone Too Far

Omeros: YARTEMLEA Is Off To A Blistering Start

This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Q2 Earnings Call Highlights

OMER Stock Soars 24% After-Hours On YARTEMLEA Sales Momentum, Debt Reduction And Share Buybacks